




Catalog Number:	MO22198	Host:	Mouse
Product Type:	Mouse Monoclonal IgG	Species Reactivity:	Not applicable
Immunogen Sequence:	Recombinant SARS-CoV2 S-Protein ACE2 binding domain expressed in and purified from <i>E. coli</i>	Format:	Purified antibody at 1mg/mL in 50% PBS, 50% glycerol plus 5mM NaN3
Applications:	Immunofluorescent: 1:3,000-5,000 Immunocytochemistry: 1:3,000-5,000 Western Blot: 1:1,000-2,000		

Dilutions listed as a recommendation. Optimal dilution should be determined by investigator.

Storage: Antibody can also be aliquotted and stored frozen at -20° C in a manual defrost freezer for six months without detectable loss of activity. The antibody is stable at 2° - 8° C for 1 year. Avoid repeated freeze-thaw cycles.

Application Notes



Description/Data:

In late 2019 a novel infectious disease was discovered in Wuhan, China which was quickly recognized to be caused by a previously unknown RNA coronavirus. The virus was very rapidly isolated, the full RNA sequence determined and put on-line on the 10th of January 2020. The sequence revealed that the virus was most closely related to certain bat coronaviruses and the severe acute respiratory syndrome (SARS) coronavirus. Immediately biotechnology companies and research institutes used the RNA sequence information to generate vaccine candidates. The SARS virus was known to enter and infect human cells by means of the so-called spike or S-protein which binds to the extracellular domain of the angiotensin converting enzyme 2 (ACE2) protein, which is then internalized bringing the virus into the cell. Cryoelectron microscopy and binding studies quickly determined that the S-protein of SARS-CoV2 is structurally similar to that of the SARS virus and also binds to the ACE2 receptor, albeit with higher affinity than the S-protein of SARS.

FOR RESEARCH USE ONLY


NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com

Images: Immunofluorescence: Immunofluorescent analysis of HEK293 cells transfected with pCI-Neo-Mod vector (5) including SARS-CoV2-bd cDNA and stained with mouse mAb to SARS-CoV2-bd, MO22198, dilution 1:1,000, in red. The blue is Hoechst staining of nuclear DNA. The antibody reveals expression of SARS-CoV2-bd protein only in transfected cells. DAPI reveals the nuclear DNA of both transfected and non-transfected cells.

Western Blot: Western blot analysis of HEK293 cell lysates using mouse mAb to SARS-CoV2-bd protein dilution 1:3,000 in green: [1] protein standard, [2] non-transfected cells, [3] cells transfected with pCI-Neo-Mod containing the SARS-CoV2-bd cDNA, and [4] cells transfected with pCI-Neo-GFP vector expression construct containing containing the SARS-CoV2-bd cDNA.



FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com